4//SEC Filing
Kooij Louise Frederika 4
Accession 0000950170-25-046962
CIK 0001936258other
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 5:29 PM ET
Size
9.5 KB
Accession
0000950170-25-046962
Insider Transaction Report
Form 4
Kooij Louise Frederika
Chief Accounting Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2025-03-26+8,269→ 23,269 total - Award
Restricted Stock Unit
2025-03-26+8,269→ 8,269 total→ Ordinary Shares (8,269 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-03-26−8,269→ 0 total→ Ordinary Shares (8,269 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share.
- [F2]Upon grant, all of the RSUs were fully-vested.
- [F3]The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.
Documents
Issuer
NewAmsterdam Pharma Co N.V.
CIK 0001936258
Entity typeother
Related Parties
1- filerCIK 0002004379
Filing Metadata
- Form type
- 4
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 5:29 PM ET
- Size
- 9.5 KB